UBS Group
BCLI

UBS Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

UBS Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,380
Closed -$13.9K – 10339
2025
Q2 		$13.9K Buy
12,380
+12,127
+4,793% +$13.6K ﹤0.01% 8681
2025
Q1 		$319 Sell
253
-3,219
-93% -$5.7K ﹤0.01% 9824
2024
Q4 		$7.88K Buy
3,472
+3,305
+1,979% +$6.1K ﹤0.01% 8444
2024
Q3 		$575 Sell
167
-307
-65% -$1.45K ﹤0.01% 8882
2024
Q2 		$2.41K Buy
474
+307
+184% +$2.3K ﹤0.01% 8363
2024
Q1 		$1.41K Hold
167
– – ﹤0.01% 8139
2023
Q4 		$683 Sell
167
-76
-31% -$228 ﹤0.01% 8550
2023
Q3 		$728 Buy
243
+76
+46% +$1.73K ﹤0.01% 8309
2023
Q2 		$5.15K Sell
167
-333
-67% -$13.8K ﹤0.01% 7470
2023
Q1 		$24.8K Hold
500
– – ﹤0.01% 6924
2022
Q4 		$12.3K Hold
500
– – ﹤0.01% 8289
2022
Q3 		$33K Sell
500
-20
-4% -$1K ﹤0.01% 6753
2022
Q2 		$22K Buy
520
+6
+1% +$270 ﹤0.01% 6742
2022
Q1 		$26K Sell
514
-446
-46% -$21.9K ﹤0.01% 7131
2021
Q4 		$58K Buy
960
+226
+31% +$11.1K ﹤0.01% 6761
2021
Q3 		$37K Sell
734
-200
-21% -$10.5K ﹤0.01% 6564
2021
Q2 		$54K Sell
934
-153
-14% -$8.18K ﹤0.01% 6350
2021
Q1 		$63K Buy
1,087
+332
+44% +$25.1K ﹤0.01% 6322
2020
Q4 		$51K Buy
755
+188
+33% +$25.6K ﹤0.01% 6158
2020
Q3 		$144K Sell
567
-563
-50% -$115K ﹤0.01% 4978
2020
Q2 		$190K Buy
1,130
+963
+577% +$104K ﹤0.01% 4834
2020
Q1 		$12K Hold
167
– – ﹤0.01% 6808
2019
Q4 		$11K Hold
167
– – ﹤0.01% 7226
2019
Q3 		$10K Sell
167
-171
-51% -$10.1K ﹤0.01% 7151
2019
Q2 		$20K Buy
+338
New +$19.7K ﹤0.01% 6602
2019
Q1 		– Sell
-130
Closed -$7K – 7724
2018
Q4 		$7K Buy
130
+95
+271% +$4.68K ﹤0.01% 7398
2018
Q3 		$2K Buy
+35
New +$2.12K ﹤0.01% 7728
2018
Q2 		– Sell
-103
Closed -$5K – 7974
2018
Q1 		$5K Sell
103
-24
-19% -$1.21K ﹤0.01% 7217
2017
Q4 		$7K Sell
127
-143
-53% -$8.55K ﹤0.01% 7212
2017
Q3 		$17K Buy
270
+122
+82% +$7.89K ﹤0.01% 6561
2017
Q2 		$9K Sell
148
-240
-62% -$14.8K ﹤0.01% 6829
2017
Q1 		$25K Buy
388
+328
+547% +$17.1K ﹤0.01% 5978
2016
Q4 		$2K Buy
+60
New +$2.08K ﹤0.01% 7491
2016
Q3 		– Sell
-359
Closed -$13K – 7669
2016
Q2 		$13K Buy
+359
New +$12.6K ﹤0.01% 6607
2016
Q1 		– Sell
-68
Closed -$3K – 7636
2015
Q4 		$3K Hold
68
– – ﹤0.01% 7863
2015
Q3 		$2K Hold
68
– – ﹤0.01% 8059
2015
Q2 		$4K Sell
68
-212
-76% -$12.6K ﹤0.01% 7952
2015
Q1 		$19K Buy
280
+236
+536% +$14.9K ﹤0.01% 7023
2014
Q4 		$3K Buy
+44
New +$2.31K ﹤0.01% 9220

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

UBS Group's BCLI Position: Q3 2025 in Review

UBS Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 12,380 shares — an estimated $13.9K sold.

UBS Group first reported a position in BCLI in Q4 2014 and held it in 39 quarters. The position peaked at $190K in Q2 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • UBS Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 12,380 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $13.9K.
  • UBS Group first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 39 quarters.
  • UBS Group's BRAINSTORM CELL THERAPUTC position peaked at $190K in Q2 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.